Julian Kaye, PhD

Treatment with LPCN 1021 restored and maintained testosterone levels at rates comparable to approved non-oral products.

Study results show that men with stable coronary heart disease or acute coronary syndrome who received testosterone replacement therapy did not experience higher rates of major adverse cardiovascular events than men who did not receive testosterone replacement therapy.

Researchers reported no association between endogenous testosterone and incident stroke and ischemic changes in men evaluated via brain MRI imaging.

Study results presented at ENDO 2015 suggest that some risk factors associated with cardiovascular disease are regulated by testosterone and estradiol, others (such as changes in LDL cholesterol and blood pressure) are not.

Researchers report that weight loss and increases in bone turnover were greater after one year among patients who underwent Roux-en-Y gastric bypass compared to patients who had laparoscopic adjustable gastric banding procedures.

Testosterone is not significantly associated with bone mineral density or fracture risk. Estrone, however, may have a role in bone health and fracture prevention in postmenopausal women.

Study results show teriparatide therapy results in changes to bone microarchitecture that, although not associated with decreased estimated bone strength, have an unknown effect on fracture risk.

Long-term denosumab therapy was associated with better outcomes compared to calcium and vitamin D supplementation alone in postmenopausal women with osteoporosis.

Bariatric surgery has been shown to reduce the long-term risk of diabetes-associated vascular disease in obese patients. According to study results presented at ENDO 2015, bariatric surgery reduced the risk of developing macrovascular events by 20% and reduced the risk of microvascular events by 50%.

Analysis indicates that current measures may underestimate predicted adult height in obese girls, and overestimate predicted adult height in obese boys.

In overweight and obese individuals without diabetes, liraglutide 3.0 mg as an adjunct to diet and exercise was associated with greater reductions in fasting and postprandial glucose compared with diet and exercise alone.

Study results show that patients who underwent Roux-en-Y gastric bypass surgery experienced greater and more rapid weight loss at 12- and 24 months post-surgery compared to patients who received the sleeve gastrectomy procedure. GB patients also experienced a larger decrease in hemoglobin within the first two months post-surgery and a sustained decrease in creatinine.

With prevalence rates for autism spectrum disorder higher than previously estimated, clinicians should be aware of recent changes in diagnostic definitions and criteria for autism spectrum disorder.

To ensure that anaphylaxis episodes are treated in a timely and effective manner, action plans should be developed and distributed to patients, family and other caregivers, and schools.

Recent approvals and ongoing research have expanded the number of treatment options available to pediatricians and their patients.

A detailed presentation at AAP 2014 covered recent hot topics in antibiotic development, microbial resistance, pneumonia treatment, fluoroquinolone safety, and the impact of antibiotic use on the gut microbiome.

The actions and experiences of staff at Children's Mercy Hospital in Kansas City, MO, provide many lessons for clinicians at other facilities who may be dealing with an increase in EV-D68 cases.

Atopic dermatitis is the most common inflammatory pediatric skin disorder, with reported incidences ranging from 10% to 20%. The principles of effect care include fixing the skin barrier, short-circuiting inflammation, decreasing itching, treating infections, and striving for prevention by addressing the triggers.

Knowledgeable practitioners can effectively discuss pathophysiology and treatment strategies for amplified pain with patients and prescribe a treatment approach that does not require drug therapy for pain or sleep aids.

The first principle of diagnosis is localization in order to optimize the differential diagnosis and avoid unnecessary testing.

What do pediatricians need to know to effectively counsel and manage children with potentially deadly food allergies?

Amid the ongoing debate over gun violence in America, what role can and shold pediatricians play as advocates for child safety?

Study results showed treatment with N-acetylcysteine did not slow the decline in lung function, reduce acute exacerbations, or improve survival compared with placebo in patients with idiopathic pulmonary fibrosis.

Results from two studies show that treatment with the novel kinase inhibitor nintedanib significantly slowed disease progression in patients with idiopathic pulmonary fibrosis (IPF). However, only one study showed nintedanib had any effect on slowing deterioration in quality of life or reducing the risk of a first acute exacerbation compared with placebo.

Recently published study results, when combined with results from previous clinical trials, show treatment with the antifibrotic drug pirfenidone slows disease progression and improves survival in patients with idiopathic pulmonary fibrosis (IPF). These findings, if they lead the FDA to reevaluate and approve this drug, could be a game changer for patients with IPF, a disease marked by a high mortality rate and few treatment options.

Combination treatment with a fixed dose of indacaterol and glycopyrronium bromide was associated with significant improvements in several measures of lung function and health status compared to placebo and tiotropium in treatment-naïve patients with COPD.

Subgroup analysis from four studies reveals treatment with a once-daily, fixed-dose combination of umeclidinium vilanterol improves lung function at 24 weeks for a broad range of patients with moderate to severe COPD.

Treatment with a fixed-dose combination of aclidinium 400 µg and formoterol 12 µg significantly improved bronchodilation in patients with moderate to severe COPD compared with aclidinium or formoterol monotherapy alone.

Study results presented at the 2014 American Thoracic Society International Conference show that treatment with rosuvastatin reduces markers of inflammation in patients with COPD after 12 weeks, but is not associated with improvements in measures of lung function.

Study results presented at the 2014 American Thoracic Society International Conference show that treatment with simvastatin did not decrease exacerbation rates or time to first exacerbation in patients with COPD.